Traded Mar 11 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Traded Feb 9, 2026 · Filed Feb 11, 2026
United Therapeutics's PRESIDENT AND COO sold $6.94M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$6,941,796
Shares × reported transaction price
103 days after results of Oct 29, 2025, 16 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | 0.0% | −0.8% | +0.9% |
| 30 days | +12.7% | −4.3% | +17.0% |
| 90 days | +22.3% | +6.7% | +15.6% |
| 180 days | +11.3% | +11.7% | −0.4% |
Past results only. Not a forecast.
Traded Mar 11 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$192K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$128K of United Therapeutics
Scheduled in advance